Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Pradeep Natarajan on Milvexian and Abelacimab vs Enoxaparin to Prevent VTE Post-Arthroplasty
Pradeep Natarajan/LinkedIn
Nov 30, 2025, 18:35

Pradeep Natarajan on Milvexian and Abelacimab vs Enoxaparin to Prevent VTE Post-Arthroplasty

Pradeep Natarajan, Director, Preventive Cardiology at Massachusetts General Hospital, shared on LinkedIn:

”Milvexian (oral FXIa inhibitor bid) and Abelacimab (FXI mAb x1) both have been shown to lower knee arthroplasty postop VTE vs enoxaparin (sc FXa and thrombin inhibitor).

In new RCT in same context, REGN7508Cat x1 was superior to enoxaparin sc daily but REGN9933A2 x1 was non-inferior.

Bleeding rates were similar but postop anemia less common for both vs enopaxarin.

– REGN7508Cat blocks the catalytic domain of FXI, so it blocks FXIa activity and FXI activation by FXIIa *and* thrombin.

This is generally similar to Abelacimab, which locks FXI in its inactive state.
– REGN9933A2 blocks the apple 2 domain of FXI, blocking FXIIa-mediated activation but permits thrombin-mediated activation.

So it’s primarily a contact pathway FXI inhibitor.

The effect estimate for reduced VTE with REGN7508Cat vs enoxaparin seems similar for Abelacimab at the higher doses in ANT-005 TKA.

Milvexian BID had lower VTE rates relative to enoxaparin only at the highest studied dose of AXIOMATIC-TKR with similar bleeding rates.

The data continue to show that the deepest inhibition of FXI (Abelacimab, now REGN7508Cat) is most favorable for postop VTE prevention after knee arthroplasty.

This study effectively demonstrates that FXI activation by both FXIIa *and* thrombin play a role in postop VTE.

In exploratory analyses, REGN7508Cat had lower VTE rates vs apixaban (oral FXa inhibitor), which is exciting to see.

Such a comparison was not performed in the Milvexian and Abelacimab postop VTE trials.”

Read the full article here.

Article: Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials

Authors: Jeffrey I. Weitz, Aaron P. Kithcart, Meagan P. O’Brien, Oren Levy, Ethan Marin, Margaret Onisko, Kusha A. Mohammadi, Dateng Li, Karoline A. Meagher, Hannah H. Chang, Benjamin A. Olenchock, David E. Gutstein, Annelise Segers, Robin S. Roberts, Marc P. Bonaca, Gary E. Raskob

Pradeep Natarajan on Milvexian and Abelacimab vs Enoxaparin to Prevent VTE Post-Arthroplasty

Stay updated on all scientific advances with Hemostasis Today.

Aaron P. Kithcart Abelacimab Annelise Segers Benjamin A. Olenchock Dateng Li David E. Gutstein Enoxaparin Ethan Marin Gary E. Raskob Hannah H. Chang Health Hematology Hemostasis Hemostasis Today Jeffrey I. Weitz Karoline A. Meagher knee arthroplasty Kusha A. Mohammadi Marc P. Bonaca Margaret Onisko Meagan P. O'Brien Medicine milvexian Oren Levy Pradeep Natarajan REGN7508Cat REGN9933A2 Robin S. Roberts thrombosis TKA VTE
NewsFeed